Do nonvitamin-K antagonist oral anticoagulants prevent stroke compared to vitamin-K antagonists in patients with atrial fibrillation in a real-world setting?
Real-world data confirms the efficacy of NOACs (dabigatran, rivaroxaban, apixaban) versus VKAs for stroke prevention in atrial fibrillation.
This meta-analysis confirms the main findings of the randomized controlled trials of dabigatran, rivaroxaban, and apixaban in the real-world setting and, hence, strengthens their validity.
Ntaios et al. (Tue,) studied this question.